Dechra Pharmaceuticals PLC, commonly known as Dechra, is a leading global veterinary pharmaceutical company headquartered in the United Kingdom. Founded in 1997, Dechra has established a strong presence in Europe, North America, and Australia, focusing on the development and marketing of high-quality products for companion animals and livestock. Specialising in veterinary medicines, Dechra offers a diverse range of core products, including anaesthetics, dermatology treatments, and nutritional supplements. What sets Dechra apart is its commitment to innovation and quality, ensuring that its products meet the highest standards of safety and efficacy. With a robust market position, Dechra has achieved significant milestones, including numerous product launches and strategic acquisitions, solidifying its reputation as a trusted partner in animal health. The company continues to lead the way in veterinary pharmaceuticals, dedicated to improving the health and well-being of animals worldwide.
How does Dechra's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Dechra's score of 62 is higher than 76% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2022, Dechra Pharmaceuticals reported total greenhouse gas emissions of approximately 144,513,000 kg CO2e globally, with specific emissions breakdowns of 7,596,000 kg CO2e for Scope 1, 4,413,000 kg CO2e for Scope 2, and a significant 319,498,000 kg CO2e for Scope 3 emissions. In the UK, the company recorded Scope 1 emissions of 489,757 kg CO2e, Scope 2 emissions of 607,104 kg CO2e, and Scope 3 emissions of 144,040 kg CO2e. Dechra has set ambitious climate commitments, aiming to reduce absolute Scope 1 and 2 GHG emissions by 42% by 2030 from a 2021 base year, and by 90% by 2050. Additionally, they plan to reduce Scope 3 GHG emissions by 51.6% per GBP value added by 2030 and by 97% by 2050. These targets are aligned with the Science Based Targets initiative (SBTi) and are designed to support the global effort to limit warming to 1.5°C. Overall, Dechra is committed to achieving net-zero greenhouse gas emissions across its value chain by 2050, demonstrating a proactive approach to sustainability within the pharmaceuticals sector.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 6,747,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 4,969,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 2,347,000 | 000,000,000 | 000,000,000 |
Dechra's Scope 3 emissions, which decreased by 34% last year and increased significantly since 2020, demonstrating supply chain emissions tracking. Nearly all of their carbon footprint comes from suppliers and value chain emissions, representing nearly all emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 17% of Scope 3 emissions.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Dechra has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


Common questions about Dechra's sustainability data and climate commitments